New drug Jevtana (Cabazitaxel) approved for metastatic Prostate cancer
The NCCN Guidelines for Prostate Cancer have been updated to include cabazitaxel with steroids as an option under systemic salvage therapy of metastatic castration-recurrent prostate cancer (category 1 designation). Cabazitaxel given with prednisone has been shown in a randomized phase III study to prolong overall survival, progression-free survival, and improve PSA and radiologic responses when compared with mitoxantrone and prednisone. Cabazitaxel is FDA approved in the post-docetaxel second line setting.
For the complete updated versions of the NCCN Guidelines(tm) and NCCN Compendium(tm), please visit NCCN.org.